Mainz Biomed: Frank Krieg-Schneider
Aug 03, 2022
Mainz Biomed has appointed Frank Krieg-Schneider as VP of development. He will lead commercialization efforts across the company's portfolio of cancer detection products including its flagship ColoAlert test. Krieg-Schneider most recently led the clinical diagnostics division at Germany's R-Biopharm. He also previously served as CEO of molecular diagnostics firm GNA Biosolutions, and prior to that spent two decades in senior management and executive roles with Qiagen, including head of R&D for diagnostic sample preparation and head of global strategic alliances.